This is my last finding:
In vivo Knock-down of the HSV-1 Latency-Associated Transcript Reduces Reactivation from Latency.
"We show that this treatment blocks reactivation in the majority of the rabbits."
There are currently two Phase 2 clinical trials of the effect of valacyclovir (i.e. Valtrex) at the NIH and University Hospital in Umeå, Sweden respectively for the sole purpose of measuring the impact to Alzheimers of taking Valacyclovir in HSV1+ individuals.
Anti-viral Therapy in Alzheimer's Disease
Feasibility and Effects of Valaciclovir Treatment in Persons With Early Alzheimer's Disease (VALZ-Pilot)
We should have some compelling evidence by about this time next year as the Swedish study has been going since 2016 and is set to conclude in April of next year. The NIH study is set to conclude in 2022 but either way, on simply the mounting causal evidence, I'm going to continue taking my antivirals.